
Brief intro:
- Author: DING Zhaowen
- Publication Date: 2023 Aug
Products/Services used in the paper
Quotation shows PackGene:was used as a negative control
Research Field:Coronavirus
AAV Serotype:pseudovirus
Animal or cell line strain:HEK293T
Abstract
Polylactic acid (PLA)-based materials with good performance in biocompatibility and biodegradation the have widely used in biomedical field, including drug delivery, tissue engineering and photothermal therapy. When the exogenous materials transmitted into the human body, various interfacial interactions between nanomaterials and biological components occur in the vasculature, pulmonary tract and gastrointestinal tract due to the long retention time and constant simulation. However, despite the efficacy of PLA-based materials, the nano-bio interaction during the transmission and the corresponding application are required to explore in depth for the rational usage and clinic guidance. This study focuses in two popular types of PLAbased materials, including two-dimensional PEGylated lamella materials and threedimensional hierarchical porous microsphere, for systemic exploration of nano-bio interaction in different disease models. The PEGylated lamella material, PEGylated poly(lactic acid) (P-PLA), despite not being internalized by vascular endothelial cells, simulated various inflammatory cytokines through L-type calcium ion channel Cav1.3, thus aggravated the atherosclerosis development while enhanced the nanomedicine extravasation and antitumor efficacy. The hierarchical porous microsphere allowed the micro-scale virus aerosol move inside through micro-scale pore, captured the virus through nano-scale pores with positive charged DOPE, thus protected the lung tissue from acute respiratory diseases such as COVID-19 and influenza A. This study clarified the complexity and diversity of nano-bio interaction in different transmission tract, and provided guidance for the rational usage of PLA-based materials in the biomedical field.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
